A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
Start Date
12/2/2025
Completion Date
3/1/2028
Summary
The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening.
Eligibility Criteria
Age Range: 18 years to 75 years
Interventions
LY4213663
LY4213663
Placebo
Placebo
Conditions
Locations
Pinnacle Research Group, LLC
Anniston, Alabama 36207
United States
Arizona Research Center
Phoenix, Arizona 85053
United States
Clinical Research of West Florida, Inc. (Clearwater)
Clearwater, Florida 33765
United States
GNP Research at Mark Jaffe, MD
Cooper City, Florida 33024
United States
Fortrea Clinical Research Unit
Daytona Beach, Florida 32117
United States
AGA Clinical Trials
Hialeah, Florida 33012
United States
Advanced Pharma CR, LLC
Miami, Florida 33417
United States
Floridian Clinical Research
Miami Lakes, Florida 33016
United States
Oasis Clinical Research
Las Vegas, Nevada 89121
United States
Universitätsklinikum Charité
Berlin, 10117
Germany